Table 1 An overview of studies meeting the inclusion criteria
First author | Year of publication | Country | Survey duration (months) | Target populations | Target sample size per population (deff) | Eligibility criteria | HCV test |
Abadie et al. [24] | 2016 | Puerto Rico | 3 | 4 | >18 years injected in last 30 days | POC antibody | |
Bacak et al. [55] | 2013 | Montenegro | 4 | 1 | 18–51 years, injected in last 30 days | POC antibody | |
Baumbach et al. [20]a | 2008 | USA/Mexico | 5 | 2 | ≥18 years, injected in last 30 days | Venipuncture antibody | |
Bouscaillou et al. [23] | 2014 | Georgia | 1 | 193 | ≥18 years, injected in last 30 days | POC antibody and RNA | |
Burt et al. [56] | 2009 | USA | 5 | 1 | >18 years, injected in last 12 months | Self report | |
Cepeda et al. [57]. | 2013 | Russia | 23 | 2 | ≥18 years, injected last 30 days, drinks alcohol | Venipuncture antibody | |
Eritsyan et al. [58]. | 2013 | Russia | 2 | 8 | 300(0) | ≥18 years, injected in last 30 days | Venipuncture antibody |
Frost et al. [21]. | 2006 | USA/Mexico | 3 | 2 | 200 | ≥18 years, injected in last 30 days | Venipuncture antibody |
Gelpi-Acosta et al. [38]. | 2011 | USA | 30 | 1 | 500 | 18–40 years, injected in last 12 months | Venipuncture antibody |
Handanagic et al. [34] | 2016 | Croatia | 4 | 3 | 350–400 | >18 years, injected in last 30 days | Venipuncture antibody |
Heimer et al. [28]. | 2014 | USA | 1 | ≥18 years, injected in last 30 days | Venipuncture antibody | ||
Hope et al. [59]. | 2011 | UK | 3 | 1 | ≥18 years, injected in last 30 days | DBS antibody and RNA | |
Jarlais et al. [60] | 2016 | Vietnam | <1 | 1 | 600 | >18 years, currently injecting | Venipuncture antibody |
Johnston et al. [25] | 2011 | Mauritius | 3 | 1b | 500(2) | ≥15 years, injected in last 30 days | Venipuncture antibody |
Judd et al. [40]. | 2009 | Serbia and Montenegro | 2 | 2 | ≥18 years, injected in last 30 days | DBS Antibody | |
Lausevic et al. [36] | 2015 | Montenegro | 1 | 376 | ≥18 years, injected in last 30 days | Venipuncture antibody | |
Li et al. [26] | 2014 | China | 1 | 362 | ≥18 years, injected in last 6 months | Venipuncture antibody | |
Mahanta et al. [61] | 2008 | India | 11 | 5 | 400 | Males ≥18 years, injected in last 6 months | DBS antibody |
Mahfoud et al. [27] | 2010 | Lebanon | 2 | 1 | ≥15 years, injected in last 12 months | DBS antibody and RNA | |
Malekinejad et al. [33] | 2011 | USA | 8 | 1 | 18–70 years, IDU in last 12 months | Self report | |
Mirzoyan et al. [37] | 2013 | Libya | 5 | 1 | ≥15 years old 30 days | Venipuncture antibody | |
Nadol et al. [22] | 2015 | Vietnam | 13 | 4 | 291–310(1.2) | ≥18 years, injected in last 30 days | Venipuncture antibody |
Paintsil et al. [41] | 2009 | Russia | 2–7 | 1 | ≥18 years, injected in last 6 months | Venipuncture antibody | |
Paquette et al. [32] | 2011 | Australia | 5 | 1 | 258(1.5) | >18 years, IDU in last 30 days | Self report |
Sarna et al. [35] | 2012 | India | 5 | 2 | 760(1.5) | Male, >16 years, IDU in last 6 months | Self report |
Solomon et al. [19] | 2015 | India | 1.5 | 15 | 1000 | ≥18 years, injected in last 2 years | Venipuncture antibody |
Stulhofer et al. [31] | 2012 | Israel | 3 | 1 | 18 to 56 years, injected in last 30 days | Venipuncture antibody | |
Tun et al. [62] | 2013 | Nigeria | 1.5 | 1 | 400(1.4) | ≥18 years, injected in last 12 months | Venipuncture antibody |
Vorobjov et al. [63] | 2009 | Estonia | 1 | ≥18 years, injected in last 2 months | Venipuncture antibody | ||
Wenz et al. [29] | 2016 | Germany | 2 | 8 | 200–400 | >16 years, injected in last 12 months | DBS antibody and RNA |
Zamani et al. [30] | 2010 | Iran | 3 | 1 | 130(1.5) | ≥18 years, injected in last 30 days | Venipuncture antibody |